+

WO1997031611A3 - Treatment of begnin prostatic hyperplasia - Google Patents

Treatment of begnin prostatic hyperplasia Download PDF

Info

Publication number
WO1997031611A3
WO1997031611A3 PCT/US1997/003228 US9703228W WO9731611A3 WO 1997031611 A3 WO1997031611 A3 WO 1997031611A3 US 9703228 W US9703228 W US 9703228W WO 9731611 A3 WO9731611 A3 WO 9731611A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
prostatic hyperplasia
methods
delivery
apoptotic
Prior art date
Application number
PCT/US1997/003228
Other languages
French (fr)
Other versions
WO1997031611A2 (en
Inventor
David T Hung
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Priority to EP97914829A priority Critical patent/EP0886524A2/en
Priority to AU21937/97A priority patent/AU2193797A/en
Publication of WO1997031611A2 publication Critical patent/WO1997031611A2/en
Publication of WO1997031611A3 publication Critical patent/WO1997031611A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)

Abstract

Novel methods for delivery of pro-apoptotic and/or anti-proliferative agents to the prostate gland for treatment of prostate disorders are disclosed. Kits for practicing the methods of the invention are also provided. The methods and kits of the invention can employ a catheter-based delivery system that uses phoresis, pressure, or both, to assist in the delivery of the pro-apoptotic and/or anti-proliferative agents to the prostate gland and/or surrounding regions.
PCT/US1997/003228 1996-03-01 1997-02-28 Treatment of begnin prostatic hyperplasia WO1997031611A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP97914829A EP0886524A2 (en) 1996-03-01 1997-02-28 Delivery of therapeutic agents to the prostate
AU21937/97A AU2193797A (en) 1996-03-01 1997-02-28 Delivery of therapeutic agents to the prostate

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US1267296P 1996-03-01 1996-03-01
US60/012,672 1996-03-01
US1281796P 1996-03-05 1996-03-05
US60/012,817 1996-03-05
US2153996P 1996-07-11 1996-07-11
US60/021,539 1996-07-11
US80718197A 1997-02-27 1997-02-27
US08/807,181 1997-02-27

Publications (2)

Publication Number Publication Date
WO1997031611A2 WO1997031611A2 (en) 1997-09-04
WO1997031611A3 true WO1997031611A3 (en) 1997-11-13

Family

ID=27486210

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/003228 WO1997031611A2 (en) 1996-03-01 1997-02-28 Treatment of begnin prostatic hyperplasia

Country Status (3)

Country Link
EP (1) EP0886524A2 (en)
AU (1) AU2193797A (en)
WO (1) WO1997031611A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794545B1 (en) 1999-04-30 2004-09-21 Slil Biomedical Corporation Conformationally restricted polyamine analogs as disease therapies
US7279502B2 (en) 1999-04-30 2007-10-09 Cellgate, Inc. Polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases
US7312244B2 (en) 1999-04-30 2007-12-25 Cellgate, Inc. Polyamine analog-amino acid conjugates useful as anticancer agents

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3454799A (en) * 1998-03-30 1999-10-18 Baylor College Of Medicine Regulated apoptosis using chemically induced dimerization of apoptosis factors
US6482943B1 (en) 1999-04-30 2002-11-19 Slil Biomedical Corporation Quinones as disease therapies
IL146125A0 (en) * 1999-04-30 2002-07-25 Slil Biomedical Corp Novel quinones as disease therapies
AU1070901A (en) * 1999-09-23 2001-04-24 Genvec, Inc. Method of treating cells of the prostate prophylactically or therapeutically
US6939896B2 (en) * 1999-12-21 2005-09-06 Astrazeneca Ab Cd45 inhibitors
US6982351B2 (en) 2001-12-07 2006-01-03 Cellgate, Inc. Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor
US7837670B2 (en) 2005-03-22 2010-11-23 Boston Scientific Scimed, Inc. Methods and devices for delivering therapeutic agents into the prostate gland

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5007897A (en) * 1989-05-30 1991-04-16 Kalb Irvin M Drug delivery catheter
WO1994006910A1 (en) * 1992-09-18 1994-03-31 Canji, Inc. Gene therapy by retroviral vector with tumor suppressive gene
EP0639573A1 (en) * 1993-08-03 1995-02-22 Hoechst Aktiengesellschaft Benzocondensed five membered heterocycles, process of their preparation, their use as drug, as diagnostic means and pharmaceuticals containing it
WO1995023141A1 (en) * 1994-02-23 1995-08-31 Pfizer Inc. 4-heterocyclyl-substituted quinazoline derivatives, processes for their preparation and their use as anti-cancer agents
EP0688766A1 (en) * 1994-06-20 1995-12-27 Hoechst Aktiengesellschaft Phenylsubstituted alkenyl-carboxylic-acid-guanidines containing perfluoroalkyl groups, process for their preparation, their use as medicament or diagnostic agent, as well as a medicament containing them

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5007897A (en) * 1989-05-30 1991-04-16 Kalb Irvin M Drug delivery catheter
WO1994006910A1 (en) * 1992-09-18 1994-03-31 Canji, Inc. Gene therapy by retroviral vector with tumor suppressive gene
EP0639573A1 (en) * 1993-08-03 1995-02-22 Hoechst Aktiengesellschaft Benzocondensed five membered heterocycles, process of their preparation, their use as drug, as diagnostic means and pharmaceuticals containing it
WO1995023141A1 (en) * 1994-02-23 1995-08-31 Pfizer Inc. 4-heterocyclyl-substituted quinazoline derivatives, processes for their preparation and their use as anti-cancer agents
EP0688766A1 (en) * 1994-06-20 1995-12-27 Hoechst Aktiengesellschaft Phenylsubstituted alkenyl-carboxylic-acid-guanidines containing perfluoroalkyl groups, process for their preparation, their use as medicament or diagnostic agent, as well as a medicament containing them

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 123, no. 25, 1995, Columbus, Ohio, US; abstract no. 332818, MIURA, M. ET AL: "Molecular mecanisms and signalling pathway of apoptosis" page 428; column 2; XP002034678 *
COHEN J.J.: "Apoptosis", IMMUNOLOGY TODAY, vol. 14, no. 3, 1993, pages 126 - 130, XP002034675 *
COHEN J.J.: "Exponential growth in apoptosis", IMMUNOLOGY TODAY, vol. 16, no. 7, 1995, pages 346 - 348, XP002034676 *
COLOMBEL M.: "Growth factors, cell proliferation and apoptosis in prostate adenoma", BIOMEDICINE & PHARMACOTHERAPY, vol. 48, no. 1 suppl, 1994, pages 25s - 26s, XP002034673 *
EASTHAM, J.A. ET AL: "In vivo gene therapy with p53 or p21 adenovirus for prostate cancer", CANCER RESEARCH, vol. 55, 1995, pages 5151 - 5155, XP002034677 *
Jikken Igaku, 1995, 13(16), 1824-7 (Japan) *
RITTMASTER R.S. ET AL: "Evidence for atrophy and apoptosis in the prostates of men given Finasteride", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, vol. 81, no. 2, February 1996 (1996-02-01), pages 814 - 819, XP002034672 *
SILVER, R.I. ET AL: "Androgen suppression therapy for benign prostatic hyperplasia", CURRENT OPINION IN UROLOGY, vol. 4, no. 1, 1994, pages 22 - 28, XP002034674 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794545B1 (en) 1999-04-30 2004-09-21 Slil Biomedical Corporation Conformationally restricted polyamine analogs as disease therapies
US7186825B2 (en) 1999-04-30 2007-03-06 Cellgate, Inc. Conformationally restricted polyamine analogs as disease therapies
US7279502B2 (en) 1999-04-30 2007-10-09 Cellgate, Inc. Polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases
US7312244B2 (en) 1999-04-30 2007-12-25 Cellgate, Inc. Polyamine analog-amino acid conjugates useful as anticancer agents

Also Published As

Publication number Publication date
WO1997031611A2 (en) 1997-09-04
EP0886524A2 (en) 1998-12-30
AU2193797A (en) 1997-09-16

Similar Documents

Publication Publication Date Title
WO1997044063A3 (en) Dha-pharmaceutical agent conjugates
TR200002773T2 (en) Smilagen and anzurogenin-D and their use for the treatment of Alzheimer's.
HK1054389A1 (en) Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of begnin prostatic hyperplasia.
ATE185971T1 (en) COMBINATION PREPARATION FOR THE TREATMENT OF HYPOGONADAL MEN AND MEN WITH HYPOPHYSIS DISEASES
CA2195093A1 (en) Use of droloxifene for the treatment of prostatic diseases, endometriosis and obesity
PL329173A1 (en) Laser application set of thomas j type
DE69739017D1 (en) Card-type registration means, registration method and apparatus for the registration means, system for generating such registration means, ciphering system and decoder therefor, and registration means
CA2255891A1 (en) Compositions and methods for treating or preventing diseases of body passageways
HK1027280A1 (en) Plant extracts for the treatment of increased boneresorption.
BR9703302A (en) Apparatus and method for the generation and use of iron ions
WO1996035784A3 (en) Chromatin-regulator genes
CA2301032A1 (en) A method of preventing or treating estrogen-dependent diseases and disorders
IT1306553B1 (en) PROCEDURE AND DEVICE FOR DETERMINING THE INTERAXIS OF THE STEERING VEHICLES.
NZ332721A (en) Use of bactericidal/permeability increasing (BPI) protein sometimes in conjunction with a thrombolytic agent to treat thrombotic disorders
WO1997031611A3 (en) Treatment of begnin prostatic hyperplasia
EP2348031A3 (en) 17-Alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienedione as antiprogestational agents
DK1071433T3 (en) 2 ', 2'-difluoronucleosides for immunosuppressive treatment and combination preparations
WO1998022101A3 (en) Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
CA2275167A1 (en) The topical use of kappa opioid agonists to treat ocular pain
ZA971861B (en) Method for producing liquid pig iron or liquid steel pre-products and plant for carrying out the method.
DZ2665A1 (en) Conjugates useful for the treatment of prostate cancer.
ZA978640B (en) Use of 1-hydroxy-2-pyridones for the treatment of saborrheic dermatitis.
ZA976852B (en) Stable dispersions of metal passivation agents and methods for making them.
AU1278600A (en) Novel therapeutic application of nicergoline
MD798F1 (en) Method of the mamma cancer treatment

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 1997914829

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97531182

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1997914829

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1997914829

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载